LES PUBLICATIONS. Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15.

Size: px
Start display at page:

Download "LES PUBLICATIONS. Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15."

Transcription

1 LES PUBLICATIONS MOLECULAR AND CELLULAR VIROLOGY OF HEPATITIS Inserm U CNRS UMR 8204 University Lille 1 - University Lille 2 Institut Pasteur de Lille affiliated to IFR 142 Responsable Jean DUBUISSON Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology, 2010, 38: Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15. Belouzard S, Madu I, Whittaker GR. Elastase activation of the SARS coronavirus spike protein at discrete sites within S2 domain. J Biol Chem, 285: Ciczora I, Callens N, Séron K, Rouillé Y, Dubuisson J. Identification of a dominant endoplasmic reticulum retention signal in yellow fever virus pre-membrane protein. J Gen Virol, 2010, 91: Goueslain L, Alsaleh K, Horrelou P, Roingeard P, Descamps V, Duverlie G, Ciczora Y, Wychowski C, Dubuisson J, and Rouillé Y. Identification of GBF1 as a cellular factor required for HCV RNA replication. J Virol, 2010, 84: Helle F, Vieyres G, Elkrief L, Popescu I, Wychowski C, Descamps V, Castelain S, Duverlie G, Dubuisson J. Role of N-linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J Virol, 2010, in press. Montserret R, Saint N, Vanbelle C, Salvay A, Simorre JP, Ebel C, Sapay N, Renisio JG, Böckmann A, Steinmann E, Pietschmann T, Dubuisson J, Chipot C, Penin F. NMR structure analysis and ion channel activity of the p7 polypeptide from hepatitis C virus. J Biol Chem, 2010, in press. Pawlotsky JM, Cocquerel L, Durantel D, Lavillette D, Lerat H, Pécheur EI, Polyak SJ, Tautz N, Thimme R. HCV research 20 years after discovery : a summary of the 16th international meeting on hepatitis c virus and related viruses. Gastroenterology, 2010, 138:6-12. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell, 2010, 102: Tews B, Popescu CI, Dubuisson J. Last stop before exit Hepatitis C assembly and release as antiviral drug targets. Viruses, 2010, 2: Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol, 2010, 84:

2 2009 Alvarez-Lajonchere L, Shoukry N, Gra B, Amado-Canizares Y, Helle F, Bedard N, Guerra I, Drouin C, Dubuisson J, Gonzalez Horta EE, Martinez G, Marante J, Cinza Z, Castellanos M, Duenas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepatitis, 2009, 16: Charrin S, Yalaoui S, Bartosch B, Cocquerel L, Franetich JF, BoucheixC, Mazier D, Rubinstein E, Silvie O. The IG domain protein CD9P-1 down-regulates CD81 ability to support plasmodium YOELII infection. J Biol Chem, 2009, 284: Dubois A, Francois C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G. Enhanced anti-hcv activity of interferon alpha 17 subtype. Virol J, 2009, 6:70. Helle F, Dubuisson J. Rôle des N-glycanes dans les fonctions des protéines d enveloppe du virus de l hépatite C. Virologie, 2009, 13: Kuzmina TI, Olenina LV, Sanzhakov MA, Farafonova TE, Abramihina TV, Dubuisson J, Sobolev BN, Kolesanova EF. Antigenicity and B-epitope mapping of hepatitis C virus envelope protein E2. Biomed Chem (Moscow), 2009, 55: Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C Virus entry. BMC Microbiol, 2009, 9:111. Roohvand F, Maillard P, Lavergne JP, Boulant S, Walic M, Andréo U, Goueslain L, Helle F, McLauchlan J, Budkowska A. Initiation of hepatitis C virus infection requires the dynamic microtubule network: Role of the viral nucleocapsid protein. J Biol Chem, 2009, 284: Tews BA, Cocquerel L. Occludin, an additional key for hepatitis C virus entry. Med Sci (Paris), 2009, 25: Tews BA, Dubuisson J. Occludin, the final essential factor for HCV entry? Future Virology, 2009, 4: Touvier T, Conte-Auriol F, Briand O, Cudejko C, Paumelle R, Caron S, Baugé E, Rouillé Y, Salles JP, Staels B, Bailleul B. LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest, 2009, 119 : Vieyres G, Angus AG, Haberstroh A, Baumert TF, Dubuisson J, Patel AH. Rapid synchronization of hepatitis C virus infection by magnetic adsorption. J Virol Methods, 2009, 157(1): Castelain S, Schnuriger A, François C, Nguyen-Khac E, Fournier C, Schmit JL, Capron D, Dubuisson J, Wychowski C, Thibault V, Duverlie G. Lower levels of HCV neutralizing antibodies in HIV/HCV-coinfected patients than in HCV-monoinfected patients. J Infect Dis, 2008, 198 : Dubuisson J, Helle F, Cocquerel L. Early steps of the Hepatitis C Virus life cycle. Cell Microbiol, 2008, 10:

3 Helle F, Dubuisson J. Hepatitis C Virus entry into host cells. Cell Mol Life Sci, 2008, 65: Helle F, Dubuisson J. Mechanism and inhibition of Hepatitis C Virus entry. J Viral Entry, 2008, 3: Helle F, Cocquerel L. L entrée du virus de l hépatite C dans ses cellules cibles. Virologie, 2008, 12: Jaffrelo L, Chabas S, Reigadas S, Pflieger A, Wychowski C, Rumi J, Ventura M, Toulmé JJ, Staedel C. A functional selection of viral genetic elements in cultured cells to identify hepatitis C virus RNA translation inhibitors. Nucleic Acids Res, 2008, 36:e95. Machida K, Kondo Y, Huang J, Chen YC, Cheng KTH, Keck Z, Foung S, Dubuisson J, Sung VMH, Lai MMC. HCV-induced Immunoglobulin Hypermutation Reduces the Affinity and Neutralizing Activities of Antibodies against HCV Envelope Protein. J Virol, 2008, 82: Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, SaCunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C. Serum derived HCV infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol, 2008, 82: Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, Pillez A, Drobecq H, Le Naour F, Charrin S, Levy S, Rubinstein E, Dubuisson J, Cocquerel L. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS ONE 3, 2008, e1866. Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits HCV entry. Cell Microbiol, 2008, 10: Voisset C, Weiss RA, Griffiths DJ. Human RNA "rumor" viruses : the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev, 2008, 72: Antoine AF, Montpellier C, Cailliau K, Browaeys-Poly E, Vilain JP, Dubuisson J. The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes. J Membr Biol, 2007, 215: Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H,. Baumert T, Dubuisson J, Wakita T. CD81 expression is important for heterogeneous HCV permissiveness of Huh7 cell clones. J Virol, 2007, 81, Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C, Dubuisson J, François C. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir Ther, 2007, 12: Castelain S, Bonte D, Penin F, Francois C, Capron D, Dedeurwaerder S, Zawadzki P, Morel V, Wychowski C, Duverlie G. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. J Med Virol, 2007, 79:

4 Chapel C, Garcia C, Bartosh B, Roingeard P, Zitzmann N, Cosset FL, Dubuisson J, Dwek RA, Trépo C, Zoulim F, Durantel D. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol, 2007, 88: Chevalier C, Saulnier A, Benureau Y, Flechet D, Delgrange D, Colbere-Garapin F, Wychowski C, Martin A. Inhibition of Hepatitis C Virus Infection in Cell Culture by Small Interfering RNAs. Mol Ther, 2007, 15: Ciczora Y, Callens N, Penin F, Pécheur EI, Dubuisson J. The transmembrane domains of HCV envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol, 2007, 81: Couturier C, Sarkis C, Séron K, Belouzard S, Chen P, Lenain A, Corset L, Dam J, Vauthier V, Dubart A, Mallet J, Froguel P, Rouillé Y, Jockers R. Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents dietinduced obesity. Proc Natl Acad Sci USA, 2007, 104: Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. Gen Virol, 2007, 88: Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol, 2007, 13: Duverlie G, Wychowski C. Cell culture systems for the hepatitis C virus. World J Gastroenterol, 2007, 13: Fournier C, Duverlie G, Francois C, Schnuriger A, Dedeurwaerder S, Brochot E, Capron D, Wychowski C, Thibault V, Castelain S. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J, 2007, 4:35. Gatignol A, Dubuisson J, Wainberg MA, Cohen EA, Jean-Luc Darlix JL. New pandemics: HIV and AIDS, HCV and chronic hepatitis, Influenza virus and flu. Retrovirology, 2007, 4:8. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hcv antibodies is modulated by specific glycans on the E2 envelope protein. J Virol, 2007, 81: Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuison J, Persson M. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl. Acad Sci USA, 2007, 104: Lavie M, Goffard A, Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol, 2007, 9: PhD François HELLE Directeur de thèse : J Dubuisson "Les N-glycanes du Virus de l'hépatite C protègent contre la neutralisation mais sont une cible thérapeutique potentielle" 27 septembre 2007

5 David DELGRANGE Directeur de thèse : C Wychowski "Etude de la multiplication de la souche JFH-1 du virus de l hépatite C (VHC) en cellules Huh-7. Adaptation et sélection de mutations permettant une production rapide et massive du VHC. Localisation subcellulaire de protéines du VHC. Mise en évidence de clones cellulaires résistants à l infection par le VHC" 21 septembre 2007 Vera ROCHA Directeur de thèse : L Cocquerel "Identification d EWI-2wint, un partenaire de CD81 qui inhibie l entrée du VHC" 26 septembre 2007 HDR Ngoc VU-DAC "Rôle des lipoprotéines, transfert lipidique et mécanismes d entrée du VHC dans les hépatocytes" Laurence COQUEREL "Identification et caractérisation d'un inhibiteur de l entrée du virus de l'hépatite C" Karin SERON "Etude de différents aspects du trafic membranaire : de la levure Saccharomyces cerevisiae à l'obésité humaine"

The autophagy machinery is required to initiate hepatitis C virus infection. Marlène Dreux

The autophagy machinery is required to initiate hepatitis C virus infection. Marlène Dreux The autophagy machinery is required to initiate hepatitis C virus infection Marlène Dreux Hepatitis C virus life cycle HCV particles internalization RNA replication RNA translation ER HCV assembly and

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

AUCUN CONFLIT D'INTERET

AUCUN CONFLIT D'INTERET Lysophosphatidylcholine acyltransferase 1 () is downregulated by hepatitis C virus: impact on production of lipo-viro-particles Matthieu LEMASSON, Frauke BEILSTEIN, Véronique PENE, Sylvie DEMIGNOT & Arielle

More information

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Fat and Viral Liver Disease

Fat and Viral Liver Disease Fat and Viral Liver Disease Francesco Negro Viropathology Unit University of Geneva Medical Center Geneva, Switzerland Mainz, September 20, 2008 Steatosis and HBV Steatosis in HBV infection: prevalence

More information

Innovazione farmacologica e farmacologia clinica

Innovazione farmacologica e farmacologia clinica Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology

More information

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah

More information

Viruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope

Viruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope Viruses Chapter 10: Viruses Lecture Exam #3 Wednesday, November 22 nd (This lecture WILL be on Exam #3) Dr. Amy Rogers Office Hours: MW 9-10 AM Too small to see with a light microscope Visible with electron

More information

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta

More information

Co-infected health-care workers

Co-infected health-care workers Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care

More information

Custom Antibody Services

Custom Antibody Services prosci-inc.com Custom Antibody Services High Performance Antibodies and More Broad Antibody Catalog Extensive Antibody Services CUSTOM ANTIBODY SERVICES Established in 1998, ProSci Incorporated is a leading

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods

Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES PKS Chan 陳 基 湘 S Ma 文 子 光 SM Ngai 倪 世 明 Key Messages 1. Subjects recovered from SARS-CoV infection retain memory of cellular immune response to epitopes

More information

Hing wars. During World War II, there was a series of hepatitis outbreaks

Hing wars. During World War II, there was a series of hepatitis outbreaks Hepatitis C: Toward a Cure and Eradication 1 CHARLES M. RICE Head, Laboratory of Virology and Infectious Disease Scientific and Executive Director Center for the Study of Hepatitis C Rockefeller University

More information

Hepatitis C Vaccines: Are we making progress?

Hepatitis C Vaccines: Are we making progress? Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify

More information

A novel polarized cell culture model to study HCV infection

A novel polarized cell culture model to study HCV infection A novel polarized cell culture model to study HCV infection Sandrine Belouzard Centre d Infection et d Immunité de Lille 15 ième réunion du réseau national hépatites Paris- 30 janvier 2015 HCV entry and

More information

Hepatitis C Virus Inactivation

Hepatitis C Virus Inactivation Hepatitis C Virus Inactivation PD Dr. Eike Steinmann Centre for Experimental and Clinical Infection Research Institute of Experimental Virology, Twincore* *joint venture between Medical School Hannover

More information

Introduction. Genetic variability a major challenge for vaccine development. Abstract Summary

Introduction. Genetic variability a major challenge for vaccine development. Abstract Summary Development of hepatitis C virus vaccines: challenges and progress 1 2 * Françoise Stoll-Keller, Heidi Barth 3, Samira Fafi-Kremer 1 2, Mirjam B. Zeisel 1, Thomas F. Baumert 1 4 1 Interaction virus-hôte

More information

KMS-Specialist & Customized Biosimilar Service

KMS-Specialist & Customized Biosimilar Service KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal

More information

The immunogenic vaccine against HCV and HBV

The immunogenic vaccine against HCV and HBV National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis

More information

TRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013

TRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013 A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE MICE AND EXERT AN EARLY ANTIVIRAL EFFECT IN HBV TOLERANT

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235

More information

Positive impact of HCV treatment initiation on health outcomes in injecting drug users

Positive impact of HCV treatment initiation on health outcomes in injecting drug users Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction

More information

FIGHTING AIDS AT THE GATE

FIGHTING AIDS AT THE GATE FIGHTING AIDS AT THE GATE T h e r a m p a n t s p r e a d o f H I V i n f e c t i o n a c r o s s t h e g l o b e i s n o l o n g e r t h e m e d i a c r i s i s o f t h e m o m e n t. B u t A I D S h

More information

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

A white paper for consideration by the NIAID Microbial Sequencing Program

A white paper for consideration by the NIAID Microbial Sequencing Program Hepatitis C Virus Sequencing: Viral evolution, immune recognition and vaccine development. A white paper for consideration by the NIAID Microbial Sequencing Program Todd M. Allen, Ph.D. Assistant Professor

More information

MicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control

MicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control MicroRNA formation mirna s are processed from several precursor stages Mammalian genomes seem to have 100 s of mirna s Nucleotides in positions 2-8 of an mirna are considered the mirna seed 5 Methyl-G

More information

Liver Disease and Therapy of Hepatitis B Virus Infections

Liver Disease and Therapy of Hepatitis B Virus Infections Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin

More information

Alison Stewart 11/12/06 Prokaryotic Cells, Eukaryotic cells and HIV: Structures, Transcription and Transport Section Handout Discussion Week #7

Alison Stewart 11/12/06 Prokaryotic Cells, Eukaryotic cells and HIV: Structures, Transcription and Transport Section Handout Discussion Week #7 Alison Stewart 11/12/06 Prokaryotic Cells, Eukaryotic cells and HIV: Structures, Transcription and Transport Section Handout Discussion Week #7 Compare and contrast the organization of eukaryotic, prokaryotic

More information

RNA Viruses. A Practical Approac h. Alan J. Cann

RNA Viruses. A Practical Approac h. Alan J. Cann RNA Viruses A Practical Approac h Alan J. Cann List of protocols page xiii Abbreviations xvii Investigation of RNA virus genome structure 1 A j. Easton, A.C. Marriott and C.R. Pringl e 1 Introduction-the

More information

Mid-Clinical Stage Antiviral Drug Development Company

Mid-Clinical Stage Antiviral Drug Development Company BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au

More information

Structure and Function of DNA

Structure and Function of DNA Structure and Function of DNA DNA and RNA Structure DNA and RNA are nucleic acids. They consist of chemical units called nucleotides. The nucleotides are joined by a sugar-phosphate backbone. The four

More information

Viral Replication. Viral Replication: Basic Concepts

Viral Replication. Viral Replication: Basic Concepts Viral Replication Scott M. Hammer, M.D. Viral Replication: Basic Concepts Viruses are obligate intracellular parasites Viruses carry their genome (RNA or DNA) and sometimes functional proteins required

More information

Chapter 5: Organization and Expression of Immunoglobulin Genes

Chapter 5: Organization and Expression of Immunoglobulin Genes Chapter 5: Organization and Expression of Immunoglobulin Genes I. Genetic Model Compatible with Ig Structure A. Two models for Ab structure diversity 1. Germ-line theory: maintained that the genome contributed

More information

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.

More information

HBV DNA < monitoring interferon Rx

HBV DNA < monitoring interferon Rx Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute

More information

Single celled organisms

Single celled organisms Single celled organisms Single Celled Organisms Some organisms, unlike plants and animals, consist of only one cell. These organisms are said to be unicellular An amoeba is another name given to an organism

More information

Viral Safety of Plasma-Derived Products

Viral Safety of Plasma-Derived Products Viral Safety of Plasma-Derived Products SLIDE 1 This presentation will cover viral validation studies for plasma-derived products. FDA requires that the manufacturing process for biopharmaceutical products

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015

L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 Demographics Luis Rivero Pinelo MD LMCC, CCFP, FCFP, Fellow SRPC, CSPQ Shawville- Québec Aux États Unis, la prévalence est présente

More information

General presentation

General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)

More information

01 02 03 04 05 06 Haemophilus influenza 07 08 09 Proc. Natl. Acad. Sci. U.S.A. Proc. Acad. Natl. Sci. U.S.A. Nature Science Anal. Chem. Anal.Chem Nuc. Acids Res Anal. Chem Nature Science Haemophilus influenzae

More information

Final Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.

Final Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism. Central Dogma Final Review Section Week 10 DNA RNA Protein DNA DNA replication DNA RNA transcription RNA Protein translation **RNA DNA reverse transcription http://bass.bio.uci.edu/~hudel/bs99a/lecture20/lecture1_1.html

More information

Application of Neutralization Fingerprinting in Antibody Epitope Prediction and Delineating Antibody Recognition in HIV-1 Sera

Application of Neutralization Fingerprinting in Antibody Epitope Prediction and Delineating Antibody Recognition in HIV-1 Sera Application of Neutralization Fingerprinting in Antibody Epitope Prediction and Delineating Antibody Recognition in HIV-1 Sera Gwo-Yu Chuang Structural Bioinformatics Section Vaccine Research Center/NIAID/NIH

More information

The public health risk of influenza in pigs recent insights, key knowledge gaps

The public health risk of influenza in pigs recent insights, key knowledge gaps The public health risk of influenza in pigs recent insights, key knowledge gaps Prof. Kristien Van Reeth Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium H1N1, H3N2 and

More information

NS5B Sequencing and Phenotypic Resistance Assays for HCV Subtypes 1a and 1b

NS5B Sequencing and Phenotypic Resistance Assays for HCV Subtypes 1a and 1b NS5B Sequencing and Phenotypic Resistance Assays for HCV Subtypes 1a and 1b 5th Intl. Workshop on Hepatitis C Resistance & New Compounds Jacqueline Reeves NS5B Resistance Assays for HCV Subtypes 1a and

More information

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425

More information

THÈSE présentée par :

THÈSE présentée par : UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE _Sciences de la vie (ED414) [ Institute de virologie, Inserm U748 ] THÈSE présentée par : [ MUHAMMAD NAUMAN ZAHID ] soutenue le : 27 Avril 2012 pour obtenir le

More information

Publikationsliste Claudia Götz

Publikationsliste Claudia Götz Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography

More information

Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans

Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans Schwaiger Julia Clinical Institute of Virology 29.06.2009 1 Thank you! Franz X.

More information

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Molecular Diagnosis of Hepatitis B and Hepatitis D infections Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication

More information

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works. November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also

More information

When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation

When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation Karen S. Anderson MD PhD Associate Professor, Biodesign Institute Arizona State University Mayo Clinic Arizona Conflicts of Interest

More information

IMMUNOLOGY OF HIV INFECTION AND AIDS. Interactions between HIV and the immune system

IMMUNOLOGY OF HIV INFECTION AND AIDS. Interactions between HIV and the immune system IMMUNOLOGY OF HIV INFECTION AND AIDS Interactions between HIV and the immune system Basic Statistics United States In the U.S. in 2010, 1.1 million people were living with HIV infection. About 50,000 people

More information

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models

More information

Case Finding for Hepatitis B and Hepatitis C

Case Finding for Hepatitis B and Hepatitis C Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center

More information

Hepatitis C virus: Why an Enigma?

Hepatitis C virus: Why an Enigma? Review Article imedpub Journals http://www.imedpub.com Hepatitis C virus: Why an Enigma? Abstract Hepatitis C virus was identified as a distinct disease from Hepatitis A virus and Hepatitis B virus in

More information

Lecture 8. Protein Trafficking/Targeting. Protein targeting is necessary for proteins that are destined to work outside the cytoplasm.

Lecture 8. Protein Trafficking/Targeting. Protein targeting is necessary for proteins that are destined to work outside the cytoplasm. Protein Trafficking/Targeting (8.1) Lecture 8 Protein Trafficking/Targeting Protein targeting is necessary for proteins that are destined to work outside the cytoplasm. Protein targeting is more complex

More information

Hepatitis C virus (HCV), the causative agent of hepatitis C,

Hepatitis C virus (HCV), the causative agent of hepatitis C, Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization Jason Alexander Ji-Xhin

More information

Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007

Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007 Chikungunya: An emerging outbreak from East Africa to Indian Ocean, 2004-2007 A. Flahault, G. Aumont, V Boisson, X de Lamballerie, F. Favier, B.A. Gaüzère, D. Fontenille, S. Journeaux, V. Lotteau, C. Paupy,

More information

Cytosolic lipid droplets: link to the development of insulin resistance and increased production of VLDL1

Cytosolic lipid droplets: link to the development of insulin resistance and increased production of VLDL1 Cytosolic lipid droplets: link to the development of insulin resistance and increased production of VLDL1 Sven-Olof Olofsson, MD, PhD Insulin resistance is an important risk factor for the development

More information

RNAi Shooting the Messenger!

RNAi Shooting the Messenger! RNAi Shooting the Messenger! Bronya Keats, Ph.D. Department of Genetics Louisiana State University Health Sciences Center New Orleans Email: bkeats@lsuhsc.edu RNA interference (RNAi) A mechanism by which

More information

LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES

LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES Introduction to immunology. LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES Today we will get to know: The antibodies How antibodies are produced, their classes and their maturation processes Antigen recognition

More information

Treatment Options for Hepatitis C in the Post Transplant Patient

Treatment Options for Hepatitis C in the Post Transplant Patient Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut

More information

Immunity and how vaccines work

Immunity and how vaccines work 1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms

More information

VIRUSES AND CANCER. Michael Lea

VIRUSES AND CANCER. Michael Lea VIRUSES AND CANCER 2012 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review

More information

(ii) They are smaller than bacteria, and this can pass through bacteriological filter.

(ii) They are smaller than bacteria, and this can pass through bacteriological filter. Viruses Definition: Obligate intracellular parasite composed of: Nucleic acid - either DNA or RNA & Protein coat. Characteristics of viruses Viruses are the most primitive cellular and non-cytoplasmic

More information

BioMmune Technologies Inc. Corporate Presentation 2015

BioMmune Technologies Inc. Corporate Presentation 2015 BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical

More information

Required Text: Tortora, Funke, and Case. Microbiology, An Introduction, 9 th ed. Benjamin Cummings, 2007.

Required Text: Tortora, Funke, and Case. Microbiology, An Introduction, 9 th ed. Benjamin Cummings, 2007. Department of Biology Introduction to Microbiology Biol 132 (3 credit hours) Dr. Kathryn Sutton, Assistant Professor of Biology Spring, 2007 M 9-9:50; CBH Room 203 General Information Office Location CBH

More information

Viral Infection: Receptors

Viral Infection: Receptors Viral Infection: Receptors Receptors: Identification of receptors has come from expressing the gene for the receptor in a cell to which a virus does not normally bind -OR- By blocking virus attachment

More information

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,

More information

Chapter 20: Antimicrobial Drugs

Chapter 20: Antimicrobial Drugs Chapter 20: Antimicrobial Drugs 1. Overview of Antimicrobial Drugs 2. Antibacterial Drugs 3. Antiviral Drugs 4. Drugs for Eukaryotic Pathogens 1. Overview of Antimicrobial Drugs Antibiotics An antibiotic

More information

Understanding the immune response to bacterial infections

Understanding the immune response to bacterial infections Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY

More information

HuCAL Custom Monoclonal Antibodies

HuCAL Custom Monoclonal Antibodies HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

20.3 Diseases Caused by Bacteria and Viruses

20.3 Diseases Caused by Bacteria and Viruses 20.3 Diseases Caused by Bacteria and Viruses Lesson Objectives Explain how bacteria cause disease. Explain how viruses cause disease. Define emerging disease and explain why emerging diseases are a threat

More information

SYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University

SYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University SYMPOSIUM June 15, 2013 Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Bette Korber Los Alamos National Labs HIV evolution and the neutralizing antibody response We have recently

More information

Recent advances of 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28

Recent advances of 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between

More information

AN INTRODUCTION TO IMMUNOLOGY. Paul Thomas Unit 1 Department of Immunology St. Jude Children s Research Hospital

AN INTRODUCTION TO IMMUNOLOGY. Paul Thomas Unit 1 Department of Immunology St. Jude Children s Research Hospital AN INTRODUCTION TO IMMUNOLOGY Paul Thomas Unit 1 Department of Immunology St. Jude Children s Research Hospital CATEGORIES OF PATHOGENS Viruses (~0.2 microns) Bacteria (1-2 microns) Parasites (Millimeters)

More information

Micro RNAs: potentielle Biomarker für das. Blutspenderscreening

Micro RNAs: potentielle Biomarker für das. Blutspenderscreening Micro RNAs: potentielle Biomarker für das Blutspenderscreening micrornas - Background Types of RNA -Coding: messenger RNA (mrna) -Non-coding (examples): Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear

More information

João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil

João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/

More information

D Candotti. Institut National de la Transfusion Sanguine Dept. Agents Transmissibles par le Sang Paris, France

D Candotti. Institut National de la Transfusion Sanguine Dept. Agents Transmissibles par le Sang Paris, France Molecular characterization of hepatitis B virus strains infecting blood donors with high HBsAg and undetectable HBV DNA levels: implications for blood safety and screening policy D Candotti Institut National

More information

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School

More information

Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il

Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Experience CEO at N. Danenberg Holding (2000) Ltd) 2000 - Present (13 years) Investment Consulting Firm Consultant at Bonzai Holding Ltd.

More information

Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine

Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine Enveloped Virus Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine World Vaccine Congress Asia June 2015 Forward-Looking Statement Disclaimer This presentation

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

ELISA BIO 110 Lab 1. Immunity and Disease

ELISA BIO 110 Lab 1. Immunity and Disease ELISA BIO 110 Lab 1 Immunity and Disease Introduction The principal role of the mammalian immune response is to contain infectious disease agents. This response is mediated by several cellular and molecular

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Diabetes and Drug Development

Diabetes and Drug Development Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin

More information

CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS

CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS Although the process by which a functional gene for immunoglobulin HEAVY and LIGHT CHAINS is formed is highly unusual, the SYNTHESIS, POST- TRANSLATIONAL PROCESSING

More information

LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection

LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection Hepatitis and Retrovirus LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HCV Ab is Your solution LIAISON XL murex HCV Ab main features

More information

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune

More information

Vaccines Researches for the Future:

Vaccines Researches for the Future: ITMO Microbiologie et maladies infectieuses Vaccines Researches for the Future: The corevac initiative Pr Brigitte AUTRAN Institute Infection-Cancer-Immunity, UPMC, Paris Pr Jean François Delfraissy Institute

More information

Name Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in

Name Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in DNA, RNA, Protein Synthesis Keystone 1. During the process shown above, the two strands of one DNA molecule are unwound. Then, DNA polymerases add complementary nucleotides to each strand which results

More information

AERES report on the research unit

AERES report on the research unit Section des Unités de recherche AERES report on the research unit Fonction structure et inactivation d ARN bactériens From the University Rennes 1 INSERM December 2010 Section des Unités de recherche AERES

More information

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1: Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture

More information

Chapter 8. Summary and Perspectives

Chapter 8. Summary and Perspectives Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe

More information

BIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2015

BIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2015 THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2015 Sara M. Johnson PhD Candidate Respiratory Syncytial Virus Uses CX3CR1 as a Cellular Receptor on Primary Human Airway Epithelial

More information

Compartmentalization of the Cell. Objectives. Recommended Reading. Professor Alfred Cuschieri. Department of Anatomy University of Malta

Compartmentalization of the Cell. Objectives. Recommended Reading. Professor Alfred Cuschieri. Department of Anatomy University of Malta Compartmentalization of the Cell Professor Alfred Cuschieri Department of Anatomy University of Malta Objectives By the end of this session the student should be able to: 1. Identify the different organelles

More information